Objectives: To report the clinical outcomes for patients with implants treated for peri-implantitis who subsequently received supportive care (supportive peri-implant/ periodontal therapy) for at least 3 years.
| INTRODUC TI ON
Peri-implantitis is defined as the presence of inflammation in the soft tissues in addition to loss of supporting bone around an osseointegrated implant (Lindhe & Meyle, 2008) . Controversy regarding the global prevalence of peri-implantitis exists largely due to the wide range of case definitions used across studies (Salvi, Cosgarea & Sculean, 2017) . Nevertheless, it is recognized that peri-implantitis is not an uncommon finding. A recent cross-sectional study identified patients from the Swedish implant register (n > 24,716) who had implants in situ for 9 years and assessed the prevalence of moderate to severe peri-implantitis to be 15% (Case definition: bleeding on probing (BOP), suppuration and >2 mm of peri-implant bone loss) in 596 patients who attended a clinical examination out of 900 invitees (Derks et al., 2016) ; and a recent systematic review estimated a prevalence of 22% (Derks & Tomasi, 2015) across 11 studies.
Furthermore, there is general concern that the incidence of periimplantitis may increase as more implants are being placed by a greater number of clinicians with varying expertise. Therefore, as highlighted in the 11th European Workshop for Periodontology (Tonetti, Chapple, Jepsen & Sanz, 2015) , there is a need for research to identify effective protocols for prevention and treatment of peri-implantitis. In addition, evaluation of effective supportive care protocols to maintain peri-implant tissue health once peri-implantitis is treated is also required.
Heitz-Mayfield and Mombelli (2014) in 2014 investigated periimplantitis treatment success at 12 months in a systematic review of seven studies, concluding that whilst favourable short-term outcomes were reported in the majority of patients; nonresolution, progression or recurrence could also occur.
Numerous peri-implantitis treatment protocols with clinical efficacy have been documented, including nonsurgical, surgical, resective, regenerative and combined approaches. However, the most effective management protocol across the general population or in specific patient groups has not been identified (Chan, Lin, Suarez, MacEachern & Wang, 2014; Daugela, Cicciu & Saulacic, 2016; Esposito, Grusovin & Worthington, 2012b; Heitz-Mayfield & Mombelli, 2014; Khoshkam et al., 2013 Khoshkam et al., , 2016 Mahato, Wu & Wang, 2016; Renvert, Polyzois & Rutger Persson, 2013; Suarez-Lopez Del Amo, Yu & Wang, 2016) . It is likely that heterogeneity related to study design, patient characteristics, defect characteristics, implant design, prosthesis design, operator experience, clinical protocols, outcome measures and disease definitions have complicated data assessment. In addition, length of follow-up is a significant confounding factor, with Esposito and coworkers finding that recurrence of peri-implantitis occurred in up to 100% of cases in some of the study environments (Esposito et al., 2012b) . In contrast, Renvert and coworkers found that stable clinical results could be achieved up to 5 years after initial therapy but highlighted that adequate oral cleanliness across this period appeared to be an essential prerequisite (Renvert et al., 2013) .
Authors agree that extended follow-up periods are required to allow adequate assessment of stable treatment outcomes over time (Heitz-Mayfield & Mombelli, 2014; Khoshkam et al., 2016; Mahato et al., 2016) .
The role of supportive periodontal therapy (SPT) in stabilizing periodontal disease over the long term has been accepted for many years (Lindhe & Nyman, 1984; Matuliene et al., 2008) , with recent evidence also concluding that "erratic" SPT attendees had a significantly higher risk of tooth loss compared with those who attended regularly (Lee, Huang, Sun & Karimbux, 2015) . Regarding peri-implant outcomes and supportive therapy, Monje and coworkers investigated outcomes across 13 studies, finding that less frequent supportive care was correlated with an increased incidence of peri-implantitis at the implant level. However, this finding was confounded by whether there was a history of periodontal disease .
It is hypothesized that over the long term, supportive care influences the outcome of implants in general and those that have been treated for peri-implant disease specifically.
The aim of this systematic review was to explore the question:
In patients with osseointegrated dental implants, who were enrolled in supportive peri-implant/periodontal therapy (SPT) for at least 3 years, following treatment for peri-implantitis, what proportion of patients and implants is estimated to experience success, survival or peri-implantitis recurrence?
| MATERIAL S AND ME THODS
The focus question, PICO, search design and selection process are outlined in Tables 1 and 2 and are summarized below. The proposed methods were registered with PROSPERO (CRD42017071602), and reporting has been guided by PRISMA. The search was completed in April 2017. Multiple electronic databases (MEDLINE (Ovid), Embase (Ovid), The Cochrane Library, Nonindexed OVID citations), grey literature (conference proceedings, expert contact, study registers), reference lists (included articles, relevant reviews) and selected journals were scrutinized systematically, without language restriction to identify relevant data for independent review. Dedicated electronic search strategies combined textwords, indexing terms (MESH or EMTREE), multipurpose fields, adjacency operators, truncations and Boolean operators.
Selection criteria were broad during identification and screening to decrease search specificity (low agreement between investigators anticipated, decreased risk of omitting relevant articles) and specific during inclusion to increase search precision (high agreement between investigators anticipated, relevant articles included). Clinical investigations where at least 10 participants with osseointegrated implants that required treatment for peri-implantitis and who were subsequently enrolled in a SPT for at least 3 years were included.
Review articles were excluded.
The primary outcome was survival at the patient and implant level. Secondary outcomes were success, peri-implantitis recurrence, and implant loss at the patient and implant level. To report those outcomes, number of patients and implants in each category were extracted at 3 years, and other time intervals if reported.
Outcome definitions were:
• Survival-implant presence, regardless of the health of the surrounding tissues.
• Success-if defined by the authors.
• Peri-implantitis recurrence-if defined by the authors.
• Implant loss-implants that were removed for any reason, including those unrelated to peri-implantitis.
The data extraction form, risk of bias assessment form and explanatory instructions were drafted, trialled (two investigators) modified (two investigators) and completed (in duplicate, independently).
Discrepancies were resolved by discussion, with authors also contacted to seek additional information.
Data extraction included the methodology, participant demographics, implant details, author's outcome definitions, periimplantitis treatment method, SPT method, primary outcomes, secondary outcomes and other unexpected outcomes that could be of interest. 
Risk of bias was assessed on a modified Newcastle-Ottawa Scale (NOS). The criteria were customized for number of study groups (one or multiple) and assessment of subjective outcomes specific to this review (peri-implant probing, radiograph assessment, peri-implantitis recurrence definition and failure definition) ( Table 3 ). The impact of potential bias on outcomes was explored qualitatively. 
| Statistics and data presentation

| RE SULTS
| Systematic search
The systematic search flow is outlined in Figure 1 . Of 5,754 studies from multiple electronic databases, six studies from grey literature searches and one study from hand searching were screened (total n = 5,761). Eighty-three records were identified as potentially relevant during screening, 65 records were excluded through independent full-text review (Kappa = 0.94). All corresponding researchers were contacted to request clarification or further information. Four records were excluded as double-data, with the most relevant data retained for analysis (Froum, Rosen, Wang, Froum & Vinayak, 2018; Romeo, Lops, Chiapasco, Ghisolfi & Vogel, 2007; Roos-Jansåker, Lindahl, Persson & Renvert, 2011; Schwarz, Hegewald, John, Sahm & Becker, 2013) . Eighteen studies were included in qualitative assessments, with 13 in quantitative assessments. Additional records were consulted if data had been presented in related publications, and these are listed in Cochrane fields of ".ti", ".ab" and ".kw" were used to search the title, abstract and index term for the Cochrane Library
Note. mp (multipurpose field: title, original title, abstract, subject heading, name of substance, and registry word fields); adj3 (adjacency operator: retrieves records where terms are within 3 words of each other); * (truncation operator); sh (MeSH subject heading field), ab (abstract field), ti (title field), kw (keyword field).
potentially relevant articles gathered) and eligibility assessments (Kappa = 0.94, high agreement). and supportive care during follow-up. The majority of studies (n = 15) were small convenience samples (range 16-38 participants, 19-86 implants) of patients referred for peri-implantitis treatment. One study followed 100 participants with 179 implants (Carcuac et al., 2017) , and two studies followed 100 (Froum, Froum & Rosen, 2015) and 245 participants (Charalampakis, Rabe, Leonhardt & Dahlen, 2011) respectively, but it was unclear how many were followed for at least 3 years. Average participant age ranged between 44.9 and 66.3 years, with age ranges also reported from 22 to 87 years.
| Qualitative assessment
| Study characteristics
Studies were prospective (n = 16) and retrospective (n = 2), followed one participant group (n = 11) or multiple participant groups (n = 7), and were completed in University (n = 9), private practice (n = 6) and combined environment (n = 3).
| Outcomes
Studies reported outcomes of implant success (n = 5, Table 5 ), survival (n = 13, Figures 2 and 3) and disease recurrence (n = 2) at the implant-level, patient-level or both. No studies evaluated patient-reported outcomes.
| Methodological Heterogeneity
Peri-implantitis definitions, peri-implantitis treatment protocols, success definitions and recurrence definitions varied considerably between groups, contributing to marked methodological heterogeneity between studies. However, participants were treated equally within studies and within study groups, reducing heterogeneity within the data. The between-study variations impact on how results are interpreted, inter-related and translated into practice.
Across the studies, all peri-implantitis case definitions included the presence of clinical signs of inflammation and bone loss, but the thresholds defined for bone loss and probing depths were heterogeneous.
Peri-implantitis treatment protocols differed across all categories: pretreatment phase; surgical approach (i.e., resective, regenerative, combination); implant surface decontamination method; biomaterials used; adjunctive treatment (e.g., soft tissue grafting);
and peri-operative antimicrobials.
Definitions for success were reported by five studies and varied markedly (Table 5) . For this reason, it was not possible to assess implant-and patient-level success quantitatively. Studies with strict definition generally reported lower success figures, but studies with less strict definitions did not necessarily achieve better outcomes.
The ECSucc calculated from the data reported in each study for "successfully" treated implants ranged from 34% to 57% (at 3 years), 71% to 75% (at 5 years) and 7% to 41% (at 7 years) across studies.
However, at these time points, the majority of implants survived, and remained in situ ( Figure 2 ).
Disease "recurrence" was described in two of the 18 papers (Heitz-Mayfield et al., 2016; Serino, Turri & Lang, 2015) . HeitzMayfield and coworkers defined recurrence of disease where implants required additional treatment (i.e., with PD > 5 mm with concomitant BoP or suppuration and/or continued bone loss), which occurred in 12% (three of 24 patients) at 5 years. Serino and coworkers reported that none of the implants (86 patients) which obtained healthy peri-implant tissues following treatment had recurrence of disease, which was described as increased probing depth (Serino et al., 2015) .
| Supportive care protocols
Few studies provided detailed information about the supportive care regimen during follow-up, while some described the recall frequency; operator; instrumentation; and individual risk analysis performed. One study used soft tissue grafting during supportive care to augment keratinized peri-implant mucosa for some patients (Roccuzzo, Pittoni, Roccuzzo, Charrier & Dalmasso, 2017) . No studies compared supportive care protocols.
| Factors influencing treatment outcome
Two studies reported treatment success for different implant surfaces (Carcuac et al., 2017; Roccuzzo et al., 2017 ; Table 5 ). In one study implants with a rough titanium plasma-sprayed surface (TPS)
had lower success at 7 years than implants with a moderately rough surface (sandblasted large-grit acid etched [SLA] ), but similar survival (Roccuzzo et al., 2017) . In the second study implants with modified implant surfaces had lower success at 3 years compared to implants with a nonmodified surface (Carcuac et al., 2017) .
| Risk of bias assessment
The 18 included studies were assessed for methodological risks that may impact on the results (Figure 4 ). The NOS was modified to apply to both multiple and single group studies. Ten studies reported on a single patient group and eight reported on multiple patient groups.
Fourteen of the studies (78%) met over 80% of the criteria and were considered to have low risk of bias. All studies included participants in a manner that reduced risk of bias (Domain 1: Selection), with the participants comparable with each other within all studies (Domain 2: Comparability). However, assessments of outcomes were not always standardized and definitions of outcome measures were not always clearly reported across the studies (Domain 3: Outcome). Over 80% (16 of 18) of the studies did not clearly define peri-implantitis TA B L E 3 Risk of bias assessment form, modified from NOS. Studies with more than one group could attract 13 stars (*), and studies with a single group could attract 12 stars (*) 
| Quantitative assessment
Quantitative assessment of survival at the implant-(n = 13 studies, Pooled meta-analysis results showed implant-level ECSurv of 99.95% at 3 years (n = 7 studies), 99.97% at 4 years (n = 3 studies) and 91.82% at 5 years (n = 4 studies). Corresponding 95% CIs 2. Some subjects were lost to follow-up, but in your opinion this was unlikely to introduce bias or be the result of selective reporting. Authors provided reasons for lost to follow-up where practical and these indicate that such losses were unlikely to introduce bias. (State the number that were lost to follow-up and the total number in the study; the percentage lost to follow-up; reasons for lost to follow-up in the details box) (*)
3. Follow-up rate was high, and there was no description of those lost (blue legend, n = 7 studies), 4 year (red legend, n = 4 studies), 5 year (green legend, n = 4 studies) and 7 year (yellow legend, n = 2 studies) subgroups. Data for nine studies appeared once in the plot, and data for four studies appeared twice in the plot (n = 3, reported at multiple time points, n = 1, two study groups analysed). Seven studies reported 100% survival and these data points are clustered at the peak of three of the funnels (3, 4 and 5 year). Data was skewed or potentially skewed at all time points, meaning that it was likely that small patient cohorts with less favourable outcomes existed, but remained either unpublished or difficult to find. Therefore, the pooled results likely overestimate the true clinical effect and care should be taken when applying the pooled estimate to patient groups.
| D ISCUSS I ON
This review assessed clinical outcomes in patients treated for peri-implantitis who were enrolled in a supportive care program for at least 3 years, with 3, 4, 5 and 7 year results collated. This review shows that after 3, 4, 5, and 7 years the great majority of patients enrolled in a supportive care program (SPT), with regular professional biofilm removal at both implants and teeth, will not lose their implants. This review did not aim to identify the most effective peri-implantitis treatment protocol or supportive care
regimen, or to quantify risk factors that may modify outcomes.
However, as there was considerable heterogeneity within and between studies with respect to the study design (peri-implantitis definition, outcome definitions, treatment protocols, supportive care protocols) and population characteristics (patient, implant and prosthesis characteristics), these factors are examined further in the discussion.
The perception among clinicians that peri-implantitis treatment is unpredictable and may not lead to successful clinical outcomes is not uncommon. In a systematic review (Esposito, Grusovin & Worthington, 2012a) it was found that recurrence of peri-implantitis in up to 100% of treated cases occurred in some studies with a follow-up longer than 1 year. In contrast, the present systematic review shows that favourable treatment outcomes documented in studies with 12-month results (Heitz-Mayfield & Mombelli, 2014) may be Supportive care: APB: air-powder abrasive with sodium bicarbonate powder; FMD: full-mouth debridement; OHI: oral hygiene instruction.
TA B L E 4 Study description
Authors/Year
TA B L E 4 (Continued)
TA B L E 5 Implant-level success for the longest follow-up time reported, and success definitions as reported Other abbreviations: BL: bone loss, BoP: bleeding on probing, ECSucc: estimated cumulative success, LTF: loss to follow-up, N: number, NR: not reported, PD: peri-implant probing depth, Succ: success, Sup: suppuration, TPS: titanium plasma sprayed, SLA: sandblasted large grit acid-etched.
F I G U R E 2 Forest plot of the estimated cumulative survival of dental implants treated for peri-implantitis across 3, 4, 5 and 7 years F I G U R E 3 Forest plot of the estimated cumulative survival of dental implants in patients treated for peri-implantitis across 3, 4, 5 and 7 years maintained over the medium to long term (3-7 years), when patients are enrolled in a supportive care program.
| 3-7-year outcomes
Across the studies, anti-infective treatment protocols aimed at implant surface decontamination with or without a reconstructive approach using bone graft/substitutes resulted in clinical improvements for the majority of patients and implants. It should be recognized however, that some studies in this review documented the need for additional interventions (connective tissue grafting, surgical intervention, systemic antimicrobials) in some patients, to achieve the desired outcome (Roccuzzo et al., 2017) or manage disease recurrence (Heitz-Mayfield et al., 2016; Zablotsky, 1998) .
The 3-year treatment outcomes were favourable with high patient-and implant-level survival. However, in several studies where multiple follow-up time points were available, additional implant loss was noted with time due to disease progression resulting in the removal of the implants (Froum et al., 2015; Heitz-Mayfield et al., 2016; Roccuzzo et al., 2017) .
The implant-level and patient-level pooled meta-analyses showed that over 90% of implants in over 85% of patients that had treatment were expected to still have their implants after 5 years.
At 7 years there was less evidence, but data still indicated that over 80% of patients with treated implants might retain their implants.
Although results are not definitive, the review suggests that anti-infective protocols will stabilize those infections for the medium-to long term for the majority of patients, and as such, pursuing treatment could be considered to be worthwhile.
Five papers defined success, with each using composite criteria relating to BoP, suppuration, and probing depth (n = 5), bone level (n = 4) and recession (n = 1). Due to the heterogeneity of success criteria, it
was not possible to pool data or make meaningful comparisons. While complete resolution of disease, as defined by the total absence of BoP, may not be a requirement for treatment success, one study observed that absence of bleeding/suppuration on probing was predictive of stable bone levels 3 years after treatment (Carcuac et al., 2017) .
Across the 18 studies, disease recurrence was not commonly dis- The quality of conduct of the included studies was generally high, with over 75% assessed to have low risk of bias. However, the quality of reporting in some areas, in particular outcome definitions was low. This hindered data extraction and has reduced the potential utility of this systematic review.
| Anti-infective treatment
Anti-infective treatment protocols described included a pretreatment phase (nonsurgical supramucosal biofilm removal) followed by decontamination of the implant surface using a range of techniques with and without antiseptics. Implant surface decontamination was performed during surgical access. Peri-operative systemic antimicrobials were prescribed in the majority of studies. Postoperative infection control included the use of antiseptic rinsing for periods of several weeks following treatment. Supportive care protocols all involved professional biofilm removal at implants and teeth at varying time intervals from three monthly to annually. Some studies described recall frequency based on an individual risk assessment. There was no indication that recall frequency was related to patient attrition. While there were no studies comparing supportive care protocols it appears that the regular and thorough removal of biofilm at implants and teeth is necessary for a positive treatment outcome.
| Confounding factors
Local factors which may influence local plaque control and hence the outcome of peri-implantitis treatment include: implant placement/positioning; prosthesis design; presence of keratinized mucosa; implant surface and design. The association between inadequate access for oral hygiene due to prosthesis design/contours, and the presence of peri-implantitis was previously demonstrated (Serino & Strom, 2009) . It is also important to consider access for adequate local plaque control after the peri-implantitis has been treated. Two studies in the present review excluded patients with implants considered inappropriate to treat due to either poor implant positioning (Roccuzzo et al., 2017) or inadequate contour of the prosthesis (Heitz-Mayfield et al., 2016) . In some instances, it may be appropriate to remake the implant prosthesis or remove the implant if there is no possibility to achieve adequate plaque control. during supportive care (Roccuzzo et al., 2017) . It has been suggested that the absence of an adequate band of keratinized peri-implant mucosa may negatively influence treatment outcomes due to discomfort when performing oral hygiene resulting in increased plaque accumulation (Roccuzzo, Grasso & Dalmasso, 2016) .
Implant design and surface characteristics may also influence the treatment outcome. Most studies included a variety of implant designs and surfaces and it was not possible to evaluate the effect on treatment outcome due to the heterogeneity. One study found that success following resective peri-implantitis treatment was affected by implant surface characteristics. Implants with a nonmodified ("turned") surface achieved success more frequently than implants with modified surfaces at 3 years (Carcuac et al., 2017) . In another study with 7 years follow-up of reconstructive peri-implantitis treatment using a bone substitute (deproteinized bovine bone mineral with 10% collagen), patients with TPS implant surfaces had lower implant survival and success than those with a SLA implant surface (Roccuzzo et al., 2017) .
Other possible confounding factors that could not be assessed in this review due to heterogeneity, low participant numbers and nonreporting include: patient systemic factors (e.g., diabetes, cardiovascular disease); medications; history of periodontitis; smoking status and prosthesis design.
| Limitations of the review
This review sought published and unpublished data across the peri-implantitis treatment field. Three of the included studies (20%) were identified through grey literature. This is a substantial number and indicates that multiple teams are actively researching in this field. Therefore, it is possible that additional grey data exists, but was unintentionally overlooked during the search. It also suggests that knowledge in this field will continue to evolve, possibly quickly, and care should be taken to interpret results from this review in the light of more recent evidence that was not available at its inception.
The outcomes from this review are limited by the heterogeneity between studies. The utility of results from this review is limited by the outcome measure, survival. Other outcome measures could not be assessed. Survival does not account for surrounding tissue health, tissue appearance, or patient satisfaction. Although peri-implantitis treatment can retain implants for patients, a surviving implant in one patient might be markedly different to a surviving implant in another patient.
| CON CLUS IONS
The results of this review confirm that peri-implantitis can be successfully treated in patients adhering to a supportive care programme which involves professional biofilm removal at implants and teeth. High survival rates can be achieved in the medium to long term. Implant surface may influence the treatment outcomes.
Some implants in some patients may require retreatment, adjunctive therapies or implant removal.
